Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma

PURPOSE: In the Phase III SIROCCO trial (NCT01928771), benralizumab significantly reduced asthma exacerbations and improved lung function and symptoms for patients with severe, uncontrolled eosinophilic asthma. The aim of this subgroup analysis was to evaluate efficacy and safety of benralizumab for...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Allergy Asthma Immunol Res
Autors principals: Park, Hae-Sim, Lee, Sang Haak, Lee, Sook Young, Kim, Mi-Kyeong, Lee, Byung Jae, Werkström, Viktoria, Barker, Peter, Zangrilli, James G.
Format: Artigo
Idioma:Inglês
Publicat: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6557768/
https://ncbi.nlm.nih.gov/pubmed/31172719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4168/aair.2019.11.4.508
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars